Biomarkers of mild cognitive impairment and Alzheimer's disease

Annals of the Academy of Medicine Singapore

Volumn 37, Issue 5, 2008, Pages 406-410

  Tang, Bor Luen ^a,b   Kumar, Rajeev ^b  

^a Department of Biochemistry ^*

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Alzheimer's disease; Biomarkers; Mild cognitive impairment (MCI); Tau; amyloid (A )

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; HUMAN; LIPID PEROXIDATION; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT;

EID: 45249102463     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Yaari R, Corey-Bloom J. Alzheimer's disease. Semin Neurol 2007;27: 32-41.
2. Schott JM, Kennedy J, Fox NC. New developments in mild cognitive impairment and Alzheimer's disease. Curr Opin Neurol 2006;19:552-8.
3. Holzgrabe U, Kapkova P, Alptuzun V, Scheiber J, Kugelmann E. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets 2007;11:161-79.
4. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neuro 2001;58: 1985-1992
5. Peterson RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol 2007;27:22-31.
6. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 2001;56: 37-42
7. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science2002;297:353-6. Erratum in: Science 2002;297:2209.
8. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-91.
9. Wirths O, Multhaup G, Bayer TA. A modified β-amyloid hypothesis: intraneuronal accumulation of the β-amyloid peptide-the first step of a fatal cascade. J Neurochem 2004;91:513-20.
10. Cuello AC. Intracellular and extracellular Ap, a tale of two neuropathologies. Brain Pathol 2005;15:66-71.
11. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007;27:796-807.
12. Dominguez DI, HartmannD, De Strooper B. BACE1 and presenilin:two unusual aspartyl proteases involved in Alzheimer's disease. Neurodegener Dis 2004;1:168-74.
13. Haass C. Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J 2004;23:483-8.
14. Zhang Y, McLaughlin R, Goodyear C, LeBlanc A. Selective cytotoxicity of intracellular amyloid-β peptide 1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 2002; 156:519-29.
15. Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, et al. Amyloid β-protein (Ap)l-40 protects neurons from damage induced by Aβl-42 in culture and in rat brain. J Neurochem 2003;87:609-19.
16. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005; 120:545-55.
17. Huang Y, Weisgraber KH, Mucke L, Mahley RW. Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. J Mol Neurosci 2004;23:189-204.
18. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005; 1739:198-210.
19. Mi K, Johnson GV. The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2006;3:449-63.
20. Blurton-Jones M, Laferla FM. Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res 2006;3:437-48.
21. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". Neurobiol Aging 1998;19:109-16. Erratum in: Neurobiol Aging l998;l9:285.
22. Growdon JH. Biomarkers of Alzheimer disease. Arch Neurol 1999;56:281-3.
23. Sjogren M, Andreasen N, Blennow K. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. Clin Chim Acta 2003;332:1-10.
24. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.
25. Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, et al. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004;1 11:247-72.
26. Galasko D. Biomarkers for Alzheimer's disease - clinical needs and application. J Alzheimers Dis 2005;8:339-46.
27. Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001;50:150-6.
28. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002;59:1267-72.
29. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004;61:95-102.
30. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, et al. Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999;273:5-8.
31. Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, et al. Cerebrospinal fluid amyloid beta (1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 2001 ;l 72:433-6.
32. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004;9:705-10.
33. Formichi P, Battisti C, Radi E, Federico A. Cerebrospinal fluid tau, Aβ, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol 2006;208:39-46.
34. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005;64:1294-7.
35. De Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S. et al. Longitudinal CSF and MR1 biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006;27:394-401.
36. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-34. Erratum in: Lancet Neurol 2006;5:293.
37. Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttila T. CSF Aβ42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging 2007;28:507-14.
38. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al. Prediction of Alzheimer's disease using the CSF Aβ42/ Aβ40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:316-20.
39. Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007;28: 1070-4..
40. Lewczuk P, Komhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiol Aging 2008;29:812-8.
41. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B,Jung HH, Hegi T, Nitsch RM, et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide 42. Arch Neurol 2003;60:1202-6.
42. Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol 2003;10:119-28.
43. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, et al. Amyloid β (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004;62: 1580-4.
44. Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, Kararizou E, et al. Cerebrospinal fluid tau, phospho-tau 181 and β-amyloid 1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur J Neurol 2007;14:168-73.
45. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/β-amyloid 42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64:343-9.
46. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000;57:100-5.
47. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, et al. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003;61:1185-90.
48. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003;60:958-64.
49. Borroni B, Di Luca M, Padovani A. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful? Eur J Pharmacol 2006;545:73-80.
50. Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx 2004;1:226-34.
51. Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Aβ levels do not reflect brain Aβ levels. J Neuropathol Exp Neurol 2007;66: 264-71.
52. van Oijen M, Hofman A, Soares HD, Koudstaal PJ,Breteler MM. Plasma Aβ(l-40) and Abeta(l-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006;5:655-60.
53. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, et al. Plasma levels of β-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006;27:904-5.
54. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007;64:354-62.
55. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid-β42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging. 2007 2008;29:1-11.
56. Oprisiu R, Serot JM, Godefroy O, Black SE, Fournier A. Plasma amyloid-β concentrations in Alzheimer's disease: an alternative hypothesis. Lancet Neurol 2006;5:1001-2.
57. Markesbery WR, Kryscio RJ,Lovell MA, Morrow JD. Lipidperoxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 2005;58:730-5.
58. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF. Morrow JD. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 2005;7:269-75.
59. Padovani A, Borroni B, Colciaghi F, Pastorino L, Archetti S, Cottini E, et al. Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target. Mech Ageing Dev 2001;122:1997-2004.
60. Padovani A, Borroni B, Colciaghi F, Pettenati C, Cottini E, Agosti C, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol 2002;59:71-5.
61. Borroni B, Colciaghi F, Caltagirone C, Rozzini L, Broglio L, Cattabeni F, et al. Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2-year follow-up study. Arch Neurol 2003;60:1740-4.
62. Davidsson P, Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers 2005;21:81-92.
63. D'Ascenzo M, Relkin NR, Lee KH. Alzheimer's disease cerebrospinal fluid biomarker discovery: a proteomics approach. Curr Opin Mol Ther 2005;7:557-64.
64. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006;28:155-63.
65. Davidsson P, Sjogren M. Proteome studies of CSF in AD patients. Mech Ageing Dev 2006;127:133-7.
66. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007:61: 120-9.
67. Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog 1. et al. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging 2007 (in press).
68. Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, Davies HA, et al. Novel panel of cerebrospinal fluid biomarkers forthe prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 2007;64:366-70.
69. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006;129:3042-50.
70. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH. Curry consumption and cognitive function in the elderly. Am J Epidemiol 2006;164:898-906.
71. Feng L, Ng TP, Chuah L, Niti M, Kua EH. Homocysteine, folate, and vitamin B-12 and cognitive performance in older Chinese adults: findings from the Singapore Longitudinal Ageing Study. Am J Clin Nutr 2006;84:1506-12.
72. Tham W, Auchus AP, Thong M, Goh ML, Chang HM, Wong MC, et al. Progression of cognitive impairment after stroke: one year results from alongitudinal study of Singaporean stroke patients. J Neurol Sci 2002;203-204:49-52.
73. Auchus AP, Chen CP, Sodagar SN, Thong M, Sng EC. Single stroke dementia: insights from 12 cases in Singapore. J Neurol Sci 2002;203-204:85-9.
74. Chong MS, Sahadevan S. Preclinical Alzheimer's disease: diagnosis and prediction of progression. Lancet Neurol 2005;4:576-9.
75. Chong MS, Lim WS, Sahadevan S. Biomarkers in preclinical Alzheimer's disease. Curr Opin Investig Drugs 2006;7:600-7.